Trade Alert: President Of Soleno Therapeutics Anish Bhatnagar Has Sold Stock
Trade Alert: President Of Soleno Therapeutics Anish Bhatnagar Has Sold Stock
We wouldn't blame Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders if they were a little worried about the fact that Anish Bhatnagar, the President recently netted about US$785k selling shares at an average price of US$41.34. That sale reduced their total holding by 32% which is hardly insignificant, but far from the worst we've seen.
如果索理諾治療公司(納斯達克股票代碼:SLNO)股東對總裁阿尼什·巴特納加爾最近以平均價格41.34美元淨出售股票約78.5萬美元感到擔憂,我們就不會責怪他們。此次出售使他們的總持股量減少了32%,這並非微不足道,但遠非我們所見過的最糟糕的水平。
Soleno Therapeutics Insider Transactions Over The Last Year
Soleno Therapeutics 過去一年的內幕交易
In fact, the recent sale by President Anish Bhatnagar was not their only sale of Soleno Therapeutics shares this year. Earlier in the year, they fetched US$37.01 per share in a -US$3.3m sale. That means that an insider was selling shares at slightly below the current price (US$41.09). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was 84% of Anish Bhatnagar's holding.
實際上,總裁阿尼什·巴特納加爾最近出售的股票並不是他們今年唯一一次出售Soleno Therapeutics股票。今年早些時候,他們以-330萬美元的銷售額獲得了每股37.01美元。這意味着一位內部人士正在以略低於當前價格(41.09美元)的價格出售股票。如果內部人士一直在賣出,特別是如果他們賣出低於當前價格,我們通常認爲這是負面的,因爲這意味着他們認爲較低的價格是合理的。但是,儘管內幕銷售有時令人沮喪,但這只是一個微弱的信號。值得注意的是,此次出售佔阿尼什·巴特納加爾持股的84%。
Insiders in Soleno Therapeutics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,索理諾療法的內部人士沒有購買任何股票。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。
Insider Ownership
內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Soleno Therapeutics insiders own about US$11m worth of shares. That equates to 0.8% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。較高的內部所有權通常會使公司領導層更加關注股東的利益。索理諾療法內部人士擁有價值約1100萬美元的股票。這相當於該公司的0.8%。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。
So What Do The Soleno Therapeutics Insider Transactions Indicate?
那麼,Soleno Therapeutics的內幕交易表明了什麼呢?
Insiders sold Soleno Therapeutics shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To that end, you should learn about the 3 warning signs we've spotted with Soleno Therapeutics (including 2 which are a bit concerning).
業內人士最近出售了索理諾療法的股票,但他們沒有購買任何股票。展望過去的十二個月,我們的數據並未顯示任何內幕買盤。內部所有權並不是特別高,因此這種分析使我們對公司持謹慎態度。因此,我們只有在仔細考慮後才會購買。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。爲此,你應該了解我們在Soleno Therapeutics中發現的3個警告信號(包括兩個有點令人擔憂的警告)。
But note: Soleno Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Soleno Therapeutics可能不是最值得購買的股票。因此,來看看這份投資回報率高、負債率低的有趣公司的免費清單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。